
Mosaic Therapeutics closes $28m series A financing
Oncology specialist Mosaic Therapeutics Ltd will use a $28m financing to push its preclinical pipeline of targeted oncology therapies for...

Carbios SAS set to licence and expand PET recycling
Carbios SAS has announced "excellent outputs" from its demonstration plant in Clermont-Ferrand and its advanced engineering study for the...

Confo Therapeutics and Lilly partner to advance CFTX-1554
Under the agreement, Confo Therapeutics BV got a $40m upfront and milestone payments totalling $590m for licencing its clinical stage angiotensin II...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Bayer AG is joining forces with Acuitas Therapeutics, Inc
Following the opening of an cell and gene therapy centre in the US, German Bayer AG opts for joining forces with Acuitas Therapeutics, Inc., a ...